2023 World Conference on Lung Cancer (Posters)-EP09.01. Feasibility and Survival Outcomes of “Salvage Surgery” for Initially Clinical Stage IV Non-small Cell Lung Cancer

EP09.01. Feasibility and Survival Outcomes of “Salvage Surgery” for Initially Clinical Stage IV Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the World Conference on Lung Cancer (WCLC) 2023 evaluated the feasibility and survival outcomes of "salvage surgery" for initially clinical stage IV non-small cell lung cancer (NSCLC). Salvage surgery refers to the surgical removal of residual or regrown primary lesions in patients who have undergone systemic therapy for advanced NSCLC.<br /><br />The study analyzed the records of 14 patients who underwent lung resection for local regrowth or residual disease between 2010 and 2022. All patients had initially received systemic treatment, and surgical resection was not part of the first-line approach.<br /><br />The median age at surgery was 55 years, and the histology of the tumors varied. The patients had received different types of systemic therapy before surgery, including epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with or without chemotherapy, chemotherapy, and a combination of chemotherapy and immune checkpoint inhibitor.<br /><br />Salvage lung resection achieved complete R0 resection in 71% of patients, and one patient had a pathological complete response. The postoperative complication rate was low, with no observed postoperative complications of any grade and no 90-day mortality.<br /><br />Systemic therapy was resumed in 71% of patients after surgery. The median progression-free survival was 1.7 years, and the overall survival was not reached. Three patients who underwent surgery following EGFR-TKI treatment survived for more than 5 years with continued systemic therapy, with a maximum survival of 10.8 years.<br /><br />The study concludes that salvage lung resections are feasible in selected patients with initially clinical stage IV NSCLC, and some patients achieved long-term outcomes. Further evaluation is needed to determine the optimal timing and candidates for salvage surgery in this patient population.

Asset Subtitle

Tomoyuki Hishida

Meta Tag

Speaker Tomoyuki Hishida

Topic Metastatic NSCLC: Local Therapies - Effects

Keywords

World Conference on Lung Cancer

feasibility

survival outcomes

salvage surgery

stage IV non-small cell lung cancer

NSCLC

lung resection

systemic therapy

progression-free survival

optimal timing